Stocksigma LogoStocksigma Logo

Ajanta Pharma Reports Robust Q2 FY'27 Results with PAT Surging 49% YoY

Ajanta Pharma posted a strong Q2 FY'27 performance, with consolidated revenue rising 33% YoY to Rs. 1,794 cr. and net profit surging 49% YoY to Rs. 388 cr

Ajanta Pharma Reports Robust Q2 FY'27 Results with PAT Surging 49% YoY

Ajanta Pharma Ltd 路 Outcome 路 30 Oct 2026, 6:32 pm

Ajanta Pharma Reports Robust Q2 FY'27 Results with PAT Surging 49% YoY Ajanta Pharma posted a strong Q2 FY'27 performance, with consolidated revenue rising 33% YoY to Rs. 1,794 cr. and net profit surging 49% YoY to Rs. 388 cr. Adjusted EBITDA expanded 47% YoY to Rs. 543 cr., achieving a 30% margin. Growth was driven by Branded Generics rising 23% YoY to Rs. 1,182 cr., US Generics surging 41% YoY to Rs. 484 cr., and Africa Institution jumping 259% YoY. For H1 FY'27, revenue reached Rs. 3,420 cr. with healthy ROCE at 41% and ROE at 31%.

Original exchange filing (PDF)

More announcements from Ajanta Pharma Ltd

All Ajanta Pharma Ltd announcements